Altogether, our data show that the activation of the mevalonate pathway in Ewing sarcoma is a direct consequence of the activation of EGR2 by EWSR1-FLI1 and that this pathway can be efficiently targeted by statins. The gene discussed is EGR2; the disease is Ewing sarcoma.